Skip to main content
. Author manuscript; available in PMC: 2017 Nov 6.
Published in final edited form as: Biochem Pharmacol. 2015 Aug 19;98(1):215–223. doi: 10.1016/j.bcp.2015.08.094

Fig. 3.

Fig. 3

Chemical compounds NSC-156306 and NSC-606170 upregulated endogenous hsa-miR-29a-3p levels and down-regulated CYP2C19 expression in HepaRG cells. Differentiated HepaRG cells were treated with 0, 10 nmol/L, or 100 nmol/L NSC-156306 or NSC-606170 and cells were harvested 48 h after treatments. Each assay was carried out using at least 3 independent experiments. *P <n0.05; **P < 0.001; DMSO, no chemical compound in DMSO reagent. (A) Unregulated expression of hsa-miR-29-3p or hsa-miR-23-3p caused by NSC-156306 or NSC-606170 treatment. Data were shown as the relative miRNA levels versus U6 snRNA. (B) Down-regulated mRNA levels of CYP2C19 caused by NSC-156306 or NSC-606170 treatment. Data were shown as relative CYP2C19 mRNA levels versus GAPDH reference. (C) Down-regulated CYP2C19 protein levels caused by NSC-156306 or NSC-606170 treatment. Data were shown as relative CYP2C19 levels versus GAPDH reference.